here’s a breakdown of the provided text, organized for clarity:
Vaccination Information:
General Side Effects: Mild side effects like pain, redness, or swelling at the injection site are common and usually temporary.If they persist, consult the health centre.
Fever After Vaccination:
Fever is common, especially after the Menb vaccine.
Consult your pediatrician for paracetamol or other medication.
Seek medical attention again if the fever is very high or lasts more than two days.
Concurrent Vaccinations: These vaccines can be given on the same day as other vaccines in the national plan, according to the child’s age.
Vaccination with Illness:
Vaccination can be postponed if the child has a moderate or severe illness.
A mild cold usually does not prevent vaccination.
Availability: Vaccines are available at all public and private vaccination centers in the country.
Cost: The vaccines are free and will be part of the national vaccination scheme.Specific Scenarios and Clarifications:
Previous meningococcal Vaccination: If your child has already completed a meningococcal vaccination scheme (e.g., through a mutualist or sanatorium), they do not need to be vaccinated again under this new plan. Health teams will check the National Vaccine Registry to confirm protection.
Completing Bexsero® Scheme:
No retroactive vaccination or completion of previous schemes will occur.
If your child was born before May 1, 2025, and has already received a dose of Menb (Bexsero®), their scheme with these new vaccines will not be completed. consult vaccination history in the system if you have doubts.
Eligibility for July 2025 Births:
Only babies born on or after May 1, 2025, will be vaccinated with Menb (Bexsero®) starting at 2 months of age from July 1, 2025.
If your child turns 4 or 6 months in July 2025, they were born before May 1, 2025, and therefore do not qualify for the new plan. They will not recieve the vaccine retroactively, and prior schemes will not be completed. You will need to manage subsequent doses privately.
Herd Immunity: While the new plan focuses on specific age groups, the expansion of coverage within the target population will indirectly benefit those not vaccinated by creating a protective effect within the community.
